Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+advanced gastric or gastroesophageal junction adenocarcinoma

被引：3

作者：

Shitara, Kohei

Bang, Yung-Jue

Iwasa, Satoru

Sugimoto, Naotoshi

Ryu, Min-Hee

Sakai, Daisuke

Chung, Hyun Cheol Cheol

Omuro, Yasushi

Kawakami, Hisato

Yabusaki, Hiroshi

Sakamoto, Yasuhiro

Nishina, Tomohiro

Inaki, Koichiro

Kuwahara, Yusuke

Suto, Fumitaka

Sugihara, Masahiro

Saito, Kaku

Kojima, Akihito

Yamaguchi, Kensei

机构：

[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[2] Seoul Natl Univ, Coll Med, Seoul, South Korea

[3] Natl Canc Ctr, Tokyo, Japan

[4] Osaka Int Canc Inst, Osaka, Japan

[5] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[6] Osaka Univ Hosp, Osaka, Japan

[7] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[8] Tokyo Metropolitan Komagome Hosp, Tokyo, Japan

[9] Kindai Univ Hosp, Osaka, Japan

[10] Niigata Canc Ctr Hosp, Niigata, Japan

[11] Osaki Citizen Hosp, Osaki, Miyagi, Japan

[12] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[13] Daiichi Sankyo, Tokyo, Japan

[14] Daiichi Sankyo, Basking Ridge, NJ USA

[15] JFCR, Canc Inst Hosp, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期

关键词：

D O I：

10.1200/JCO.2022.40.4_suppl.322

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

322

引用

页数：3

共 34 条

[21] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study
Shitara, K.
Seraj, J.
Franke, F. A.
Kawaguchi, Y.
Shen, L.
Kamio, T.
Meinhardt, G.
Tabernero, J.
ANNALS OF ONCOLOGY, 2021, 32 : S1073 - S1073
[22] Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Positive Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Progressed On or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04, DG-04): A Randomized Phase 3 Study
Shitara, Kohei
Barlaskar, Ferdous
Franke, Fabio A.
Kawaguchi, Yoshinori
Shen, Lin
Kamio, Takahiro
Meinhardt, Gerold
Tabernero, Josep
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 95 - 95
[23] Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
Andre, Fabrice
Hamilton, Erika
Loi, Sherene
Schmid, Peter
Yu, Tinghui
Lu, Shiyao
Boston, Sarice
D'Cruz, Celina
Herbolsheimer, Pia
Jhaveri, Komal
CANCER RESEARCH, 2021, 81 (04)
[24] Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
Janjigian, Yelena Y.
Oh, Do-Youn
Rha, Sun Young
Lee, Keun Wook
Steeghs, Neeltje
Chao, Yee
Di Bartolomeo, Maria
Garcia, Marc Diez
Mohammad, Nadia Haj
Stein, Alexander
McAdoo, William
Winter, Megan
Croydon, Liz
Lee, Jeeyun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[25] Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
Stein, Alexander
Lordick, Florian
Janjigian, Yelena Y.
Oh, Do-Youn
Lee, Keun-Wook
Steeghs, Neeltje
Chao, Yee
Di Bartolomeo, Maria
Garcia, Marc Diez
Mohammad, Nadia Haj
Mcadoo, William
Winter, Megan
Croydon, Elizabeth
Lee, Jeeyun
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 94 - 94
[26] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04): A randomized phase 3 study
Shitara, K.
Barlaskar, F.
Franke, F.
Kawaguchi, Y.
Shen, L.
Kamio, T.
Meinhardt, G.
Tabernero, J.
ANNALS OF ONCOLOGY, 2022, 33 : S306 - S307
[27] Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03)
Janjigian, Yelena Y.
Raoufmoghaddam, Saeed
Sztachelska, Magdalena
Winter, Megan
Das, Satya
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS424 - TPS424
[28] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)
Jhaveri, Komal
Hamilton, Erika
Loi, Sherene
Schmid, Peter
Darilay, Annie
Gao, Chen
Patel, Gargi
Wrona, Magdalena
Andre, Fabrice
CANCER RESEARCH, 2021, 81 (04)
[29] Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.
Peng, Zhi
Zhang, Xiaotian
Liang, Han
Zheng, Zhichao
Wang, Zhenning
Liu, Hao
Hu, Jiankun
Sun, Yihong
Zhang, Yanqiao
Yan, Han
Tong, Lin
Xu, Jiahui
Xie, Jessica
Ji, Jiafu
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 312 - 312
[30] Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/ metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Shen, L.
Chen, P.
Lu, J.
Wan, Y.
Zheng, Y.
Ye, F.
Yang, J.
Liu, Y.
Pan, H.
Chen, H.
Sun, M.
Fan, Q.
Yuan, Y.
Chen, K.
Sun, Z.
Tian, H.
Ye, X.
Peng, Z.
ANNALS OF ONCOLOGY, 2023, 34 : S1542 - S1543

← 1 2 3 4 →